Evidence map›Paper›PMID 41369770›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026

Fracture incidence and osteoporosis treatment in Parkinson's disease: a population-based cohort study.

Jamie L Fleet, Brooke Carter, Suzanne M Cadarette, Salimah Z Shariff, Mary E Jenkins, Jeffrey D Holmes, Christina Ziebart, Kristin K Clemens

Abstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jamie L FleetDepartment of Physical Medicine and Rehabilitation, Schulich School of Medicine and Dentistry, Western University, London, Canada. Jamie.fleet@sjhc.london.on.ca.
Brooke CarterICES Western, London Health Sciences Centre Research Institute, London, Canada.
Suzanne M CadaretteICES Central and ICES University of Toronto, Toronto, Canada.
Salimah Z ShariffICES Western, London Health Sciences Centre Research Institute, London, Canada.
Mary E JenkinsDepartment of Clinical Neurosciences, Schulich School of Medicine and Dentistry, Western University, London, Canada.
Jeffrey D HolmesSchool of Occupational Therapy, Faculty of Health Sciences, Western University, London, Canada.
Christina ZiebartSchool of Physiotherapy, Faculty of Health Sciences, Western University, London, Canada.
Kristin K ClemensICES Western, London Health Sciences Centre Research Institute, London, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals with Parkinson's disease have an increased fracture risk. We found approximately 3% of individuals newly diagnosed with Parkinson's disease have a fragility fracture in the year following diagnosis, with low rates of screening and treatment for osteoporosis. Education is required to minimize this gap for an at-risk population. PURPOSE: Individuals with Parkinson's disease (PD) have an increased risk of fractures due to increased rates of falls and osteoporosis, yet bone health in PD is often overlooked. This study described fracture rates, use of osteoporosis medications, and bone mineral density (BMD) screening in individuals newly diagnosed with PD.

methodsAdministrative data were used to conduct a population-based cohort study in individuals over 65 years of age, with newly diagnosed PD in Ontario, Canada between January 2008 and December 2023. Descriptive statistics on rates of fracture, use of osteoporosis medication, and BMD testing within the year following diagnosis were reported overall and stratified by sex. Cox proportional hazard models were adjusted for age, sex, Charlson comorbidity score, previous diagnosis of osteoporosis, history of fragility fracture, and use of corticosteroids.

resultsAfter exclusions, 28,119 individuals were included in our cohort, of whom 39.9% were female. Within 1 year of PD diagnosis, 3.1% experienced a fragility fracture (3.4 per 100 person-years), 17.6% received a prescription for an osteoporosis medication, and 9.8% received a BMD test. Rates for all outcomes were greater among females than males. In the adjusted analysis, higher fracture rates were observed in females, those aged ≥ 80 years, with prior fragility fractures, and higher comorbidity scores.

conclusionDespite elevated fracture risk, fewer than one in five individuals with PD received osteoporosis screening or treatment within a year of diagnosis. These findings highlight the need for proactive bone health strategies to prevent fragility fractures in this high-risk population.

Indexed as

OsteoporosisOsteoporotic FracturesParkinson DiseaseAgedAged, 80 and overBone DensityBone Density Conservation AgentsCohort StudiesFemaleHumansIncidenceMaleMass ScreeningOntarioBone Density Conservation AgentsBisphosphonatesBone DensityFractureOsteoporosisParkinson’s Disease

Identifiers

PMID41369770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.